Humoral and cellular responses to a fifth bivalent SARS-CoV-2 vaccine dose in patients with immune-mediated inflammatory diseases on tumour necrosis factor inhibitors: a prospective cohort study.
Ørbo HS, de Matos Kasahara T, Wolf AS, Bjørlykke KH, Sexton J, Jyssum I, Tveter AT, Solum G, Kjønstad IF, Bhandari S, Christensen IE, Kvien TK, Lind A, Kared H, Jahnsen J, Haavardsholm EA, Munthe LA, Provan SA, Vaage JT, Mjaaland S, Syversen SW, Jørgensen KK, Grødeland G, Goll GL.
Ørbo HS, et al. Among authors: wolf as.
Lancet Reg Health Eur. 2024 Nov 15;48:101121. doi: 10.1016/j.lanepe.2024.101121. eCollection 2025 Jan.
Lancet Reg Health Eur. 2024.
PMID: 39624496
Free PMC article.